🔴 Moderna is trading 7.2% down today after a sharp multi-week rally and valuation concerns

Moderna is trading 7.2% down at $71.05 following a sharp multi-week rally as concerns linger that its valuation has outpaced underlying fundamentals.

• Shares surged more than 70% over the past month, driven largely by a positive 9-0 FDA panel vote.
• Analysts are flagging potential downside risks, citing current price targets and limited long-term earnings visibility.
• The stock remains highly volatile as investors weigh recent gains against the company's long-term fundamental outlook.